China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
000999
株式のランク
#2914
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent... China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of medicinal products. Its operations span both the People's Republic of China and international markets, additionally providing various health-related services. The company's extensive product line includes a wide range of over-the-counter (OTC) medications addressing common conditions such as colds, skin issues, gastrointestinal complaints, coughs, and needs in orthopedics and pediatrics. It also provides prescription drugs, with a focus on areas like traditional Chinese medicine, oncology, cardiovascular and cerebrovascular health, digestive system disorders, orthopedics, and pediatrics. Further offerings comprise Chinese medicine injections, specialized formula granules, and anti-infective agents. These products are often marketed under popular brand families, notably 999 family medicine, Sanjiuweitai series, 999 Ganmaoling series, and 999 dermatitis series. Founded in 1999 and headquartered in Shenzhen, PRC, the company initially operated as Sanjiu Pharmaceutical Co., Ltd. before rebranding to its current name in February 2010. It functions as a subsidiary under the umbrella of China Resources (Holdings) Co., Ltd.
株価
$3.74
時価総額
$6.23B
変化（1日）
-2.11%
変化（1年）
-8.54%
国
CN
取引 China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999)
カテゴリー
Healthcare
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.（000999）の収益
Jun 2026 時点の収益 TTM: $4.76B
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. の最新の財務報告によると、現在の収益 (TTM) は $4.76B です。2024 年には $3.78B の収益があり、これは 2023 年の $3.49B と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. の収益履歴（2001 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $4.76B | 5.44% |
| 2025 | $4.52B | 19.38% |
| 2024 | $3.78B | 8.26% |
| 2023 | $3.49B | 42.90% |
| 2022 | $2.45B | 17.16% |
| 2020 | $2.09B | -1.74% |
| 2019 | $2.12B | 8.83% |
| 2018 | $1.95B | 14.22% |
| 2017 | $1.71B | 32.12% |
| 2016 | $1.29B | 6.34% |
| 2015 | $1.22B | 3.56% |
| 2014 | $1.17B | -2.29% |
| 2013 | $1.20B | 7.98% |
| 2012 | $1.11B | 28.69% |
| 2011 | $865.22M | 30.83% |
| 2010 | $661.34M | -6.96% |
| 2009 | $710.79M | 12.37% |
| 2008 | $632.54M | 35.93% |
| 2007 | $465.35M | 26.67% |
| 2006 | $367.39M | -0.13% |
| 2005 | $367.88M | 23.67% |
| 2004 | $297.46M | -7.95% |
| 2003 | $323.17M | 23.51% |
| 2002 | $261.66M | 15.95% |
| 2001 | $225.66M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $23.54B | 394.15% |
DE
|
|
| $23.73B | 398.34% |
DE
|
|
| $29.24B | 513.92% |
JP
|
|
| $5.85B | 22.80% |
CH
|
|
| $6.34B | 33.16% |
IN
|
